We analyzed publicly available RNA-Seq data from 73 melanoma patients treated with standard-of-care single-agent nivolumab or pembrolizumab (n = 41) or combination anti-PD-1 + anti-CTLA-4 (n = 32; PRJEB23709; Supplemental Table 10) (72). The gene discussed is PDCD1; the disease is melanoma.